Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S G Eckhardt

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
Leukemia|February 3, 2007
The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell linesB C Medeiros, H J Landau, M Morrow, et al.
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1997
New anticancer agentsG R Weiss, H A Burris, S G Eckhardt, et al.
British Journal of Cancer|March 5, 2009
Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling studyJ Klawitter, N Anderson, J Klawitter, et al.
Current Oncology (Toronto, Ont.)|February 14, 2012
Medullary thyroid cancer and pseudocirrhosis: case report and literature reviewB L Harry, M L Smith, J R Burton, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 1994
Induction of differentiation in HL60 cells by the reduction of extrachromosomally amplified c-mycS G Eckhardt, A Dai, K K Davidson, et al.
Anticancer Research|April 22, 2011
Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell linesJ L Spratlin, T M Pitts, G N Kulikowski, et al.
Investigational New Drugs|December 16, 1998
Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming unitsL L Siu, D D Von Hoff, A Rephaeli, et al.
British Journal of Cancer|October 29, 2011
Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumoursY Pan, R Xu, M Peach, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2005
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitorsM P Morelli, T Cascone, T Troiani, et al.
Anti-Cancer Drugs|December 10, 1999
Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming unitsM Hidalgo, E Izbicka, S G Eckhardt, et al.
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
Leukemia|February 3, 2007
The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell linesB C Medeiros, H J Landau, M Morrow, et al.
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1997
New anticancer agentsG R Weiss, H A Burris, S G Eckhardt, et al.
British Journal of Cancer|March 5, 2009
Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling studyJ Klawitter, N Anderson, J Klawitter, et al.
Current Oncology (Toronto, Ont.)|February 14, 2012
Medullary thyroid cancer and pseudocirrhosis: case report and literature reviewB L Harry, M L Smith, J R Burton, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 1994
Induction of differentiation in HL60 cells by the reduction of extrachromosomally amplified c-mycS G Eckhardt, A Dai, K K Davidson, et al.
Anticancer Research|April 22, 2011
Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell linesJ L Spratlin, T M Pitts, G N Kulikowski, et al.
Investigational New Drugs|December 16, 1998
Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming unitsL L Siu, D D Von Hoff, A Rephaeli, et al.
British Journal of Cancer|October 29, 2011
Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumoursY Pan, R Xu, M Peach, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2005
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitorsM P Morelli, T Cascone, T Troiani, et al.
Anti-Cancer Drugs|December 10, 1999
Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming unitsM Hidalgo, E Izbicka, S G Eckhardt, et al.
Pageof 7